Opendata, web and dolomites

MYELOMANEXT SIGNED

Integrated next-generation flow cytometry and sequencing to uncover the pathway of curability in multiple myeloma

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MYELOMANEXT project word cloud

Explore the words cloud of the MYELOMANEXT project. It provides you a very rough idea of what is the project "MYELOMANEXT" about.

malignant    functional    opposite    surveillance    therapy    place    group    sensitive    players    vast    multiple    incurable    professional    myeloma    longitudinally    relapses    majority    cellular    sequencing    cures    optimized    dna    believe    stem    minimal    cytometry    patients    time    equally    improvement    conduct    largely    ctcs    rna    biologically    landscape    responsible    additional    despite    generation    clones    optimal    effort    failing    coupled    clone    dramatic    hierarchical    immune    tumour    relapse    samples    genomic    irrespectively    patient    noteworthy    breaking    herein    relies    met    persistent    overcome    outcome    mm    mrd    ultra    flow    deep    driving    cscs    disease    cells    therapeutic    model    innovative    clinical    first    cell    prospective    benign    scientific    sustained    ground    chemoresistant    substantial    transformation    integrate    survival    circulating    subclones    mechanisms    residual    vs    performed    hence    signature    chemoresistance    fail    remissions    cancer    understand    unquestionable    putative    trials    expertise    scope   

Project "MYELOMANEXT" data sheet

The following table provides information about the project.

Coordinator
UNIVERSIDAD DE NAVARRA 

Organization address
address: CAMPUS UNIVERSITARIO EDIFICIO CENTRAL
city: PAMPLONA
postcode: 31080
website: www.unav.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 1˙468˙606 €
 EC max contribution 1˙468˙606 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-STG
 Funding Scheme ERC-STG
 Starting year 2016
 Duration (year-month-day) from 2016-09-01   to  2021-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSIDAD DE NAVARRA ES (PAMPLONA) coordinator 1˙468˙606.00

Map

 Project objective

Multiple myeloma (MM) represents a unique model to investigate cancer stem cells (CSCs), circulating tumour cells (CTCs), and the mechanisms of malignant transformation and chemoresistance. Despite the substantial improvement in MM patients’ outcome, the vast majority of patients eventually relapse and the disease remains largely incurable. For those patients failing to achieve deep remissions, biologically targeted research on the ultra-chemoresistant minimal residual disease (MRD) clone may allow us to understand the cellular mechanisms driving chemoresistance, and design novel therapeutic to overcome; importantly, such effort should be equally performed on two additional key players: CSCs and CTCs. On the opposite side, it is unquestionable that a selected group of patients does experience long-term survival irrespectively of the depth of response achieved, but we fail to understand the mechanisms driving sustained disease control. Is it because of persistent residual benign clones? Is it because of immune surveillance? Here, we will integrate next-generation flow cytometry and sequencing to define i) the signature of CTCs and ultra-chemoresistant MRD cells, ii) the hierarchical place of putative CSCs, iii) the genomic landscape of benign vs. malignant clones; and iv) the role of immune surveillance to achieve functional cures. Hence, we will characterize for the first-time-ever the highly-professional subclones responsible for malignant transformation, disease dissemination, and dramatic relapses after optimal response to therapy. Noteworthy, the innovative approach of this scientific proposal strongly relies on the use and expertise of highly-sensitive next-generation flow cytometry, coupled with optimized DNA- and RNA-sequencing for low-cell-numbers, and prospective patient samples longitudinally available within the scope of well-controlled clinical trials. Herein, we believe that all requirements are met to conduct this ground-breaking research program.

 Publications

year authors and title journal last update
List of publications.
2017 Yuji Mishima, Bruno Paiva, Jiantao Shi, Jihye Park, Salomon Manier, Satoshi Takagi, Mira Massoud, Adriana Perilla-Glen, Yosra Aljawai, Daisy Huynh, Aldo M. Roccaro, Antonio Sacco, Marzia Capelletti, Alexandre Detappe, Diego Alignani, Kenneth C. Anderson, Nikhil C. Munshi, Felipe Prosper, Jens G. Lohr, Gavin Ha, Samuel S. Freeman, Eliezer M. Van Allen, Viktor A. Adalsteinsson, Franziska Michor, Jesus F. San Miguel, Irene M. Ghobrial
The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma
published pages: 218-224, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2017.03.025
Cell Reports 19/1 2019-06-19
2017 B Paiva, N Puig, M T Cedena, B G de Jong, Y Ruiz, I Rapado, J Martinez-Lopez, L Cordon, D Alignani, J A Delgado, M C van Zelm, J J M Van Dongen, M Pascual, X Agirre, F Prosper, J I Martín-Subero, M-B Vidriales, N C Gutierrez, M T Hernandez, A Oriol, M A Echeveste, Y Gonzalez, S K Johnson, J Epstein, B Barlogie, G J Morgan, A Orfao, J Blade, M V Mateos, J J Lahuerta, J F San-Miguel
Differentiation stage of myeloma plasma cells: biological and clinical significance
published pages: 382-392, ISSN: 0887-6924, DOI: 10.1038/leu.2016.211
Leukemia 31/2 2019-05-27
2017 P Arana, B Paiva, M-T Cedena, N Puig, L Cordon, M-B Vidriales, N C Gutierrez, F Chiodi, L Burgos, L-L Anglada, J Martinez-Lopez, M-T Hernandez, A-I Teruel, M Gironella, M-A Echeveste, L Rosiñol, R Martinez, A Oriol, J De la Rubia, A Orfao, J Blade, J-J Lahuerta, M-V Mateos, J-F San Miguel
Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials
published pages: 971-978, ISSN: 0887-6924, DOI: 10.1038/leu.2017.320
Leukemia 32/4 2019-05-27
2016 B. Paiva, M.-T. Cedena, N. Puig, P. Arana, M.-B. Vidriales, L. Cordon, J. Flores-Montero, N. C. Gutierrez, M.-L. Martin-Ramos, J. Martinez-Lopez, E. M. Ocio, M. T. Hernandez, A.-I. Teruel, L. Rosinol, M.-A. Echeveste, R. Martinez, M. Gironella, A. Oriol, C. Cabrera, J. Martin, J. Bargay, C. Encinas, Y. Gonzalez, J. J. M. Van Dongen, A. Orfao, J. Blade, M.-V. Mateos, J. J. Lahuerta, J. F. San Miguel
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
published pages: 3165-3174, ISSN: 0006-4971, DOI: 10.1182/blood-2016-03-705319
Blood 127/25 2019-05-27
2016 Bruno Paiva, Juana Merino, Jesús F. San Miguel
Utility of flow cytometry studies in the management of patients with multiple myeloma
published pages: 511-517, ISSN: 1040-8746, DOI: 10.1097/cco.0000000000000331
Current Opinion in Oncology 28/6 2019-05-27
2016 B. Paiva, L. A. Corchete, M.-B. Vidriales, N. Puig, P. Maiso, I. Rodriguez, D. Alignani, L. Burgos, M.-L. Sanchez, P. Barcena, M.-A. Echeveste, M. T. Hernandez, R. Garcia-Sanz, E. M. Ocio, A. Oriol, M. Gironella, L. Palomera, F. De Arriba, Y. Gonzalez, S. K. Johnson, J. Epstein, B. Barlogie, J. J. Lahuerta, J. Blade, A. Orfao, M.-V. Mateos, J. F. San Miguel
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance
published pages: 1896-1906, ISSN: 0006-4971, DOI: 10.1182/blood-2015-08-665679
Blood 127/15 2019-05-27
2017 T Jelinek, R Bezdekova, M Zatopkova, L Burgos, M Simicek, T Sevcikova, B Paiva, R Hajek
Current applications of multiparameter flow cytometry in plasma cell disorders
published pages: e617, ISSN: 2044-5385, DOI: 10.1038/bcj.2017.90
Blood Cancer Journal 7/10 2019-05-27

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MYELOMANEXT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MYELOMANEXT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

CHROMREP (2019)

Dissecting the chromatin response to DNA damage in silenced heterochromatin regions

Read More  

CN Identity (2019)

Comprehensive anatomical, genetic and functional identification of cerebellar nuclei neurons and their roles in sensorimotor tasks

Read More  

RTMFRM (2019)

Room Temperature Magnetic Resonance Force Microscopy

Read More